{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:34:13Z","timestamp":1787578453021,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jiangsu Province University Philosophy and Social Science Research Project","award":["No. 2023SJYB1699"],"award-info":[{"award-number":["No. 2023SJYB1699"]}]},{"name":"Nantong University, School of Nursing and Rehabilitation College-level Research Project","award":["No. HK2025-02"],"award-info":[{"award-number":["No. HK2025-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To systematically identify patient-reported outcome measures (PROMs) used to assess health-related quality of life (HRQoL), symptoms, and disease burden in patients with multiple myeloma (MM), and to appraise their measurement properties using the COSMIN methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted in accordance with the COSMIN guideline for reviews of PROMs. Eligible studies reported PROM development, content validation, cross-cultural adaptation, or one or more measurement properties of PROMs used in adult patients with MM. Methodological quality was assessed using the COSMIN Risk of Bias checklist. The results for each measurement property were rated against the COSMIN criteria for good measurement properties, and the certainty of evidence was graded using the modified GRADE approach recommended by COSMIN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six studies involving 14 PROMs were included. The EORTC QLQ-MY20 was the most frequently evaluated MM-specific module, followed by MyPOS, HM-PRO, MDASI-MM, FACT-MM, MySIm-Q, and QLICP-MM. Evidence was most often available for internal consistency, structural validity, and hypothesis testing for construct validity. By contrast, formal evidence on measurement error, criterion validity, and cross-cultural validity was seldom reported. No PROM demonstrated uniformly high-quality evidence across all key measurement properties. The EORTC QLQ-MY20 and MyPOS showed the broadest body of supportive evidence and appear to be the most defensible options for MM-specific HRQoL assessment, although additional high-quality content validity and longitudinal measurement studies remain necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence supports the use of several MM-specific PROMs, particularly the EORTC QLQ-MY20 and MyPOS, but the overall evidence base remains uneven. Future research should prioritize patient-centered content validation, measurement-error evidence, cross-cultural validity, responsiveness, and interpretability to strengthen PROM selection for MM clinical trials and practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16341-3","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:25:11Z","timestamp":1781522711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychometric properties of patient-reported outcome measures for health-related quality of life in multiple myeloma: a systematic review based on COSMIN guidelines"],"prefix":"10.1186","volume":"26","author":[{"given":"Lili","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhishui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"5","key":"16341_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and Management of Multiple Myeloma. Rev JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"Rev JAMA"},{"key":"16341_CR2","doi-asserted-by":"publisher","unstructured":"Moreau P, Touzeau C. (2015). Multiple myeloma: from front-line to relapsed therapies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, e504\u2013e511. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.e504","DOI":"10.14694\/EdBook_AM.2015.35.e504"},{"issue":"5","key":"16341_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","volume":"23","author":"SK Kumar","year":"2025","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Costello C, D\u2019Angelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Kumar R. NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Cancer Network: JNCCN. 2025;23(5):132\u201340. https:\/\/doi.org\/10.6004\/jnccn.2025.0023.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"17","key":"16341_CR4","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1182\/bloodadvances.2022007127","volume":"6","author":"EK O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Hu BY, Richardson PG, Raje NS, El-Jawahri A. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022;6(17):4967\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2022007127.","journal-title":"Blood Adv"},{"issue":"1","key":"16341_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00520-020-05493-y","volume":"29","author":"M Kamal","year":"2021","unstructured":"Kamal M, Wang XS, Shi Q, Zyczynski TM, Davis C, Williams LA, Lin HK, Garcia-Gonzalez A, Cleeland CS, Orlowski R. Symptom burden and its functional impact in patients with symptomatic relapsed or refractory multiple myeloma. Supportive care cancer: official J Multinational Association Supportive Care Cancer. 2021;29(1):467\u201375. https:\/\/doi.org\/10.1007\/s00520-020-05493-y.","journal-title":"Supportive care cancer: official J Multinational Association Supportive Care Cancer"},{"key":"16341_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-4-79","volume":"4","author":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health","year":"2006","unstructured":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79. https:\/\/doi.org\/10.1186\/1477-7525-4-79.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"16341_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin oncology: official J Am Soc Clin Oncol. 2016;34(6):557\u201365. https:\/\/doi.org\/10.1200\/JCO.2015.63.0830.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"7","key":"16341_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","volume":"130","author":"F Efficace","year":"2017","unstructured":"Efficace F, Gaidano G, Lo-Coco F. Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? Blood. 2017;130(7):859\u201366. https:\/\/doi.org\/10.1182\/blood-2017-03-737403.","journal-title":"Blood"},{"key":"16341_CR9","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, H\u00e1jek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U. EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org, & ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2021). Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Annals oncology: official J Eur Soc Med Oncol, 32(3), 309\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","DOI":"10.1016\/j.annonc.2020.11.014"},{"issue":"24","key":"16341_CR10","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Blad\u00e9 J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955\u201362. https:\/\/doi.org\/10.1182\/blood-2016-01-631200.","journal-title":"Blood"},{"issue":"3","key":"16341_CR11","doi-asserted-by":"publisher","first-page":"e2001","DOI":"10.1016\/j.jtct.2022.11.030","volume":"29","author":"CK Ullrich","year":"2023","unstructured":"Ullrich CK, Baker KK, Carpenter PA, Flowers ME, Gooley T, Stevens S, Krakow EF, Oshima MU, Salit RB, Vo P, Connelly-Smith L, Lee SJ, Wood WA. Fatigue in Hematopoietic Cell Transplantation Survivors: Correlates, Care Team Communication, and Patient-Identified Mitigation Strategies. Transplantation Cell therapy. 2023;29(3):e2001\u20138. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.030.","journal-title":"Transplantation Cell therapy"},{"issue":"21","key":"16341_CR12","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.3390\/cancers15215157","volume":"15","author":"A Boquoi","year":"2023","unstructured":"Boquoi A, Giagounidis A, Goldschmidt H, Heinsch M, Rummel MJ, Kr\u00f6ger N, Mai EK, Strapatsas J, Haas R, Kobbe G. Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384). Cancers. 2023;15(21):5157. https:\/\/doi.org\/10.3390\/cancers15215157.","journal-title":"Cancers"},{"issue":"1","key":"16341_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12955-024-02227-0","volume":"22","author":"J Dixit","year":"2024","unstructured":"Dixit J, Gupta N, Kataki A, Roy P, Mehra N, Kumar L, Singh A, Malhotra P, Gupta D, Goyal A, Rajsekar K, Krishnamurthy MN, Gupta S, Prinja S. Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database. Health Qual Life Outcomes. 2024;22(1):26. https:\/\/doi.org\/10.1186\/s12955-024-02227-0.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"16341_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00520-025-09230-1","volume":"33","author":"M Pedersen","year":"2025","unstructured":"Pedersen M, Larsen MT, Kornblit BT, Dahl EO, Lomborg K, Tolver A, Jarden M. Effects of nurse-led symptom management in chronic myeloid malignancies: a randomized trial. Supportive care cancer: official J Multinational Association Supportive Care Cancer. 2025;33(3):196. https:\/\/doi.org\/10.1007\/s00520-025-09230-1.","journal-title":"Supportive care cancer: official J Multinational Association Supportive Care Cancer"},{"issue":"1","key":"16341_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-023-00815-9","volume":"13","author":"K Forde","year":"2023","unstructured":"Forde K, Cocks K, Wells JR, McMillan I, Kyriakou C, EORTC Quality of Life Group. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development. Blood cancer J. 2023;13(1):79. https:\/\/doi.org\/10.1038\/s41408-023-00815-9.","journal-title":"Blood cancer J"},{"issue":"7","key":"16341_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00520-024-08665-2","volume":"32","author":"RV Samala","year":"2024","unstructured":"Samala RV, Nurse DP, Chen X, Wei W, Crook JJ, Fada SD, Valent J. Effects of early palliative care integration on patients with newly diagnosed multiple myeloma. Supportive care cancer: official J Multinational Association Supportive Care Cancer. 2024;32(7):468. https:\/\/doi.org\/10.1007\/s00520-024-08665-2.","journal-title":"Supportive care cancer: official J Multinational Association Supportive Care Cancer"},{"issue":"1","key":"16341_CR17","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","volume":"12","author":"R Mina","year":"2025","unstructured":"Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, Shune L, Isufi I, Harrison SJ, Shah UA, Schecter JM, Vogel M, Lendvai N, Gries KS, Katz EG, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. Lancet Haematol. 2025;12(1):e45\u201356. https:\/\/doi.org\/10.1016\/S2352-3026(24)00320-X.","journal-title":"Lancet Haematol"},{"key":"16341_CR18","unstructured":"Li Weiqiang. (2022). Development of Quality of life measurement scale QLICP-MM (V2.0) for patients with multiple myeloma and Establishment of its Minimal Clinically Important Differences, Doctoral dissertation, Guangdong Medical University."},{"issue":"7","key":"16341_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.clml.2023.03.008","volume":"23","author":"H Beer","year":"2023","unstructured":"Beer H, Chung H, J Harrison S, Quach H, Taylor-Marshall R, Jones L, Krishnasamy M. Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study. Clin lymphoma myeloma Leuk. 2023;23(7):505\u201314. https:\/\/doi.org\/10.1016\/j.clml.2023.03.008.","journal-title":"Clin lymphoma myeloma Leuk"},{"issue":"3","key":"16341_CR20","doi-asserted-by":"publisher","first-page":"e843","DOI":"10.1097\/HS9.0000000000000843","volume":"7","author":"K Weisel","year":"2023","unstructured":"Weisel K, Dimopoulos MA, San-Miguel J, Paner A, Engelhardt M, Taylor F, Lord-Bessen J, Yip C, Greenwood M, Tang J, Cavo M. Impact of Elotuzumab Plus Pomalidomide\/Dexamethasone on Health-related Quality of Life for Patients With Relapsed\/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial. HemaSphere. 2023;7(3):e843. https:\/\/doi.org\/10.1097\/HS9.0000000000000843.","journal-title":"HemaSphere"},{"issue":"1","key":"16341_CR21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1186\/s12885-021-08453-9","volume":"21","author":"G Tremblay","year":"2021","unstructured":"Tremblay G, Daniele P, Breeze J, Li L, Shah J, Shacham S, Kauffman M, Engelhardt M, Chari A, Nooka A, Vogl D, Gavriatopoulou M, Dimopoulos MA, Richardson P, Biran N, Siegel D, Vlummens P, Doyen C, Facon T, Mohty M, Sundar J. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer. 2021;21(1):993. https:\/\/doi.org\/10.1186\/s12885-021-08453-9.","journal-title":"BMC Cancer"},{"key":"16341_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0000000000001537","author":"H Du","year":"2025","unstructured":"Du H, Jiao Q, Liu C, Wu X, Guo J, Zheng H, Zhao L. Dynamic Changes in Symptom Clusters and Symptom Networks in Patients With Multiple Myeloma: A Cross-lagged Network Analysis. Cancer Nurs. 2025. https:\/\/doi.org\/10.1097\/NCC.0000000000001537. Advance online publication.","journal-title":"Cancer Nurs"},{"issue":"6","key":"16341_CR23","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s00520-022-06896-9","volume":"30","author":"F Chen","year":"2022","unstructured":"Chen F, Leng Y, Ni J, Niu T, Zhang L, Li J, Zheng Y. Symptom clusters and quality of life in ambulatory patients with multiple myeloma. Supportive care cancer: official J Multinational Association Supportive Care Cancer. 2022;30(6):4961\u201370. https:\/\/doi.org\/10.1007\/s00520-022-06896-9.","journal-title":"Supportive care cancer: official J Multinational Association Supportive Care Cancer"},{"issue":"7","key":"16341_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/10499091221132285","volume":"40","author":"RPC Ebert","year":"2023","unstructured":"Ebert RPC, Magnus MM, Toro P, Manoel FG, Costa FF, Saad O, S. T., de Melo Campos P. Hematologic Malignancies Patients Face High Symptom Burden and Are Lately Referred to Palliative Consultation: Analysis of a Single Center Experience. Am J Hosp palliat Care. 2023;40(7):761\u20134. https:\/\/doi.org\/10.1177\/10499091221132285.","journal-title":"Am J Hosp palliat Care"},{"key":"16341_CR25","doi-asserted-by":"publisher","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, Terwee CB. Qual life research: Int J Qual life aspects Treat care rehabilitation. 2018;27(5):1147\u201357. https:\/\/doi.org\/10.1007\/s11136-018-1798-3. COSMIN guideline for systematic reviews of patient-reported outcome measures.","DOI":"10.1007\/s11136-018-1798-3"},{"key":"16341_CR26","doi-asserted-by":"publisher","unstructured":"Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, Terwee CB. Qual life research: Int J Qual life aspects Treat care rehabilitation. 2018;27(5):1171\u20139. https:\/\/doi.org\/10.1007\/s11136-017-1765-4. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures.","DOI":"10.1007\/s11136-017-1765-4"},{"key":"16341_CR27","doi-asserted-by":"publisher","unstructured":"Mokkink LB, Elsman EBM, Terwee CB. Int J Qual life aspects Treat care rehabilitation. 2024;33(11):2929\u201339. https:\/\/doi.org\/10.1007\/s11136-024-03761-6. COSMIN guideline for systematic reviews of patient-reported outcome measures version 2.0. Quality of life research:.","DOI":"10.1007\/s11136-024-03761-6"},{"issue":"1","key":"16341_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41687-024-00727-7","volume":"8","author":"EBM Elsman","year":"2024","unstructured":"Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Aiyegbusi OL, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. J patient-reported outcomes. 2024;8(1):64. https:\/\/doi.org\/10.1186\/s41687-024-00727-7.","journal-title":"J patient-reported outcomes"},{"issue":"8","key":"16341_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s11136-009-9528-5","volume":"18","author":"CB Terwee","year":"2009","unstructured":"Terwee CB, Jansma EP, Riphagen II, de Vet HC. Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments. Qual Life Res. 2009;18(8):1115\u201323. https:\/\/doi.org\/10.1007\/s11136-009-9528-5.","journal-title":"Qual Life Res"},{"issue":"1","key":"16341_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"16341_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","volume":"27","author":"CB Terwee","year":"2018","unstructured":"Terwee CB, Prinsen CAC, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, Bouter LM, de Vet HCW, Mokkink LB. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual life research: Int J Qual life aspects Treat care rehabilitation. 2018;27(5):1159\u201370. https:\/\/doi.org\/10.1007\/s11136-018-1829-0.","journal-title":"Qual life research: Int J Qual life aspects Treat care rehabilitation"},{"issue":"11","key":"16341_CR32","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisl\u00f8ff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J, EORTC Quality of Life Group. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J cancer (Oxford England: 1990). 2007;43(11):1670\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2007.04.022.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"key":"16341_CR33","doi-asserted-by":"publisher","unstructured":"Kontodimopoulos N, Samartzis A, Papadopoulos AA, Niakas D. (2012). Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma. TheScientificWorldJournal, 2012, 842867. https:\/\/doi.org\/10.1100\/2012\/842867","DOI":"10.1100\/2012\/842867"},{"issue":"6","key":"16341_CR34","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00277-014-2290-y","volume":"94","author":"JR Espinoza-Zamora","year":"2015","unstructured":"Espinoza-Zamora JR, Portilla-Espinosa CM, Labardini-M\u00e9ndez JR, Cervera E, Niesvisky R, O\u00f1ate-Oca\u00f1a LF. Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument. Ann Hematol. 2015;94(6):1017\u201324. https:\/\/doi.org\/10.1007\/s00277-014-2290-y.","journal-title":"Ann Hematol"},{"issue":"1","key":"16341_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7314\/apjcp.2016.17.1.255","volume":"17","author":"A Ahmadzadeh","year":"2016","unstructured":"Ahmadzadeh A, Yekaninejad MS, Saffari M, Pakpour AH, Aaronson NK. Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20. Asian Pac J cancer prevention: APJCP. 2016;17(1):255\u20139. https:\/\/doi.org\/10.7314\/apjcp.2016.17.1.255.","journal-title":"Asian Pac J cancer prevention: APJCP"},{"issue":"11","key":"16341_CR36","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1080\/10428194.2023.2240922","volume":"64","author":"LR Dachs","year":"2023","unstructured":"Dachs LR, Gais\u00e1n CM, Bustamante G, L\u00f3pez SG, Garc\u00eda EG, Persona EP, Gonz\u00e1lez-Calle V, Auzmendi MS, P\u00e9rez JMA, Gonz\u00e1lez Montes Y, R\u00edos Tamayo R, de Miguel Llorente D, Bernal LP, Mayol AS, Caro CC, Grande M, Fern\u00e1ndez-Nistal A, Naves A, Miguel EM O. S. Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and\/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study. Leuk Lymphoma. 2023;64(11):1847\u201356. https:\/\/doi.org\/10.1080\/10428194.2023.2240922.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"16341_CR37","doi-asserted-by":"publisher","first-page":"e20230100","DOI":"10.1590\/0034-7167-2023-0100","volume":"77","author":"LA Lorca","year":"2024","unstructured":"Lorca LA, Sacomori C, Pe\u00f1a C, Barrera C, Salazar M, Le\u00e3o I, Valladares X, Rojas C. Psychometric properties of the Chilean version of the quality of life questionnaire for multiple myeloma. Revista brasileira de enfermagem. 2024;77(1):e20230100. https:\/\/doi.org\/10.1590\/0034-7167-2023-0100.","journal-title":"Revista brasileira de enfermagem"},{"issue":"1","key":"16341_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1089\/pmr.2024.0086","volume":"6","author":"C Liu","year":"2025","unstructured":"Liu C, Wang L, Wu Y, Jiao Q, Yang B, Jian Y. Psychometric Evaluation of the Chinese Version of the Quality-of-Life Questionnaire for Patients with Multiple Myeloma. Palliat Med Rep. 2025;6(1):98\u2013104. https:\/\/doi.org\/10.1089\/pmr.2024.0086.","journal-title":"Palliat Med Rep"},{"key":"16341_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12885-015-1261-6","volume":"15","author":"TR Osborne","year":"2015","unstructured":"Osborne TR, Ramsenthaler C, Schey SA, Siegert RJ, Edmonds PM, Higginson IJ. Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS). BMC Cancer. 2015;15:280. https:\/\/doi.org\/10.1186\/s12885-015-1261-6.","journal-title":"BMC Cancer"},{"issue":"11","key":"16341_CR40","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s11136-017-1660-z","volume":"26","author":"C Ramsenthaler","year":"2017","unstructured":"Ramsenthaler C, Gao W, Siegert RJ, Schey SA, Edmonds PM, Higginson IJ. Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods. Qual life research: Int J Qual life aspects Treat care rehabilitation. 2017;26(11):2931\u201347. https:\/\/doi.org\/10.1007\/s11136-017-1660-z.","journal-title":"Qual life research: Int J Qual life aspects Treat care rehabilitation"},{"issue":"1","key":"16341_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12885-020-06730-7","volume":"20","author":"C Gerlach","year":"2020","unstructured":"Gerlach C, Taylor K, Ferner M, Munder M, Weber M, Ramsenthaler C. Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. BMC Cancer. 2020;20(1):245. https:\/\/doi.org\/10.1186\/s12885-020-06730-7.","journal-title":"BMC Cancer"},{"issue":"6","key":"16341_CR42","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jpainsymman.2011.06.019","volume":"43","author":"LI Wagner","year":"2012","unstructured":"Wagner LI, Robinson D Jr, Weiss M, Katz M, Greipp P, Fonseca R, Cella D. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manag. 2012;43(6):1094\u2013104. https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.06.019.","journal-title":"J Pain Symptom Manag"},{"key":"16341_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-6-13","volume":"6","author":"D Jones","year":"2013","unstructured":"Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol. 2013;6:13. https:\/\/doi.org\/10.1186\/1756-8722-6-13.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"16341_CR44","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12885-025-14054-7","volume":"25","author":"T Wang","year":"2025","unstructured":"Wang T, Chen W, Lin Y, Tang L, Sun J, Ge Y, Mao Y, Liu H. Psychometric properties of the Chinese version of the M.D. Anderson symptom Inventory-Multiple Myeloma Module: a translation and validation study. BMC Cancer. 2025;25(1):640. https:\/\/doi.org\/10.1186\/s12885-025-14054-7.","journal-title":"BMC Cancer"},{"issue":"12","key":"16341_CR45","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.jval.2021.06.010","volume":"24","author":"KS Gries","year":"2021","unstructured":"Gries KS, Fastenau J, Seo C, Potrata B, Iaconangelo C, Serrano D. Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma. Value health: J Int Soc Pharmacoeconomics Outcomes Res. 2021;24(12):1807\u201319. https:\/\/doi.org\/10.1016\/j.jval.2021.06.010.","journal-title":"Value health: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"16341_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fphar.2020.00209","volume":"11","author":"P Goswami","year":"2020","unstructured":"Goswami P, Oliva EN, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C, Salek S. Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. Front Pharmacol. 2020;11:209. https:\/\/doi.org\/10.3389\/fphar.2020.00209.","journal-title":"Front Pharmacol"},{"key":"16341_CR47","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3389\/fphar.2020.01308","volume":"11","author":"P Goswami","year":"2020","unstructured":"Goswami P, Oliva EN, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C, Al-Obaidi MJ, Oblak M, Salek S. Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Front Pharmacol. 2020;11:1308. https:\/\/doi.org\/10.3389\/fphar.2020.01308.","journal-title":"Front Pharmacol"},{"issue":"1","key":"16341_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s41687-025-00869-2","volume":"9","author":"S Salek","year":"2025","unstructured":"Salek S, M\u00f6ller S, Abildgaard N, Rosenberg T, Larsen MT, Asdahl P, Pedersen KK, Lassen MT, Andersen CL, Nielsen LK. Translation, cultural adaptation and validation of the Danish version of the haematological malignancy patient-reported outcome measure (HM-PRO). J patient-reported outcomes. 2025;9(1):43. https:\/\/doi.org\/10.1186\/s41687-025-00869-2.","journal-title":"J patient-reported outcomes"},{"issue":"2","key":"16341_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF00435732","volume":"2","author":"GI Ringdal","year":"1993","unstructured":"Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual life research: Int J Qual life aspects Treat care rehabilitation. 1993;2(2):129\u201340. https:\/\/doi.org\/10.1007\/BF00435732.","journal-title":"Qual life research: Int J Qual life aspects Treat care rehabilitation"},{"issue":"3","key":"16341_CR50","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin oncology: official J Am Soc Clin Oncol. 1993;11(3):570\u20139. https:\/\/doi.org\/10.1200\/JCO.1993.11.3.570.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"9","key":"16341_CR51","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","volume":"30A","author":"RK Portenoy","year":"1994","unstructured":"Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J cancer (Oxford England: 1990). 1994;30A(9):1326\u201336. https:\/\/doi.org\/10.1016\/0959-8049(94)90182-1.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"9","key":"16341_CR52","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5","volume":"88","author":"VT Chang","year":"2000","unstructured":"Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88(9):2164\u201371. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(20000501)88:9%3C2164::AID-CNCR24%3E3.0.CO;2-5.","journal-title":"Cancer"},{"issue":"5","key":"16341_CR53","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/1097-0142(20000901)89:5<1162::AID-CNCR26>3.0.CO;2-Y","volume":"89","author":"VT Chang","year":"2000","unstructured":"Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT. The memorial symptom assessment scale short form (MSAS-SF). Cancer. 2000;89(5):1162\u201371. https:\/\/doi.org\/10.1002\/1097-0142(20000901)89:5%3C1162::AID-CNCR26%3E3.0.CO;2-Y.","journal-title":"Cancer"},{"issue":"10","key":"16341_CR54","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual life research: Int J Qual life aspects Treat care rehabilitation. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual life research: Int J Qual life aspects Treat care rehabilitation"},{"issue":"6","key":"16341_CR55","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s11136-011-0018-1","volume":"21","author":"SH Kim","year":"2012","unstructured":"Kim SH, Kim HJ, Lee SI, Jo MW. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Qual life research: Int J Qual life aspects Treat care rehabilitation. 2012;21(6):1065\u201373. https:\/\/doi.org\/10.1007\/s11136-011-0018-1.","journal-title":"Qual life research: Int J Qual life aspects Treat care rehabilitation"},{"issue":"6846","key":"16341_CR56","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones NM, O\u2019Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160\u20134. https:\/\/doi.org\/10.1136\/bmj.305.6846.160.","journal-title":"BMJ"},{"issue":"1","key":"16341_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/NCC.0000000000000733","volume":"44","author":"MS Kristanti","year":"2021","unstructured":"Kristanti MS, Vernooij-Dassen M, Utarini A, Effendy C, Engels Y. Measuring the Burden on Family Caregivers of People With Cancer: Cross-cultural Translation and Psychometric Testing of the Caregiver Reaction Assessment-Indonesian Version. Cancer Nurs. 2021;44(1):37\u201344. https:\/\/doi.org\/10.1097\/NCC.0000000000000733.","journal-title":"Cancer Nurs"},{"issue":"6","key":"16341_CR58","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/00223891.2021.1887201","volume":"103","author":"L Xu","year":"2021","unstructured":"Xu L, Cheng F, Liu C, Jin R, Pan H, Zhang M, Liang Z. Psychometric Properties and Factor Structures of the CERQ, DERS, and RESE Measures: A Bifactor Approach. J Pers Assess. 2021;103(6):797\u2013806. https:\/\/doi.org\/10.1080\/00223891.2021.1887201.","journal-title":"J Pers Assess"},{"issue":"3","key":"16341_CR59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.rehab.2019.10.008","volume":"63","author":"S Negrini","year":"2020","unstructured":"Negrini S, Donzelli S, Di Felice F, Zaina F, Caronni A. Construct validity of the Trunk Aesthetic Clinical Evaluation (TRACE) in young people with idiopathic scoliosis. Annals Phys rehabilitation Med. 2020;63(3):216\u201321. https:\/\/doi.org\/10.1016\/j.rehab.2019.10.008.","journal-title":"Annals Phys rehabilitation Med"},{"issue":"10","key":"16341_CR60","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jclinepi.2005.10.015","volume":"59","author":"HC de Vet","year":"2006","unstructured":"de Vet HC, Terwee CB, Knol DL, Bouter LM. When to use agreement versus reliability measures. J Clin Epidemiol. 2006;59(10):1033\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.10.015.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"16341_CR61","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11136-011-9960-1","volume":"21","author":"CB Terwee","year":"2012","unstructured":"Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual life research: Int J Qual life aspects Treat care rehabilitation. 2012;21(4):651\u20137. https:\/\/doi.org\/10.1007\/s11136-011-9960-1.","journal-title":"Qual life research: Int J Qual life aspects Treat care rehabilitation"},{"key":"16341_CR62","doi-asserted-by":"publisher","unstructured":"Calvert, M., King, M., Mercieca-Bebber, R., Aiyegbusi, O., Kyte, D., Slade, A., Chan,A. W., Basch, E., Bell, J., Bennett, A., Bhatnagar, V., Blazeby, J., Bottomley, A.,Brown, J., Brundage, M., Campbell, L., Cappelleri, J. C., Draper, H., Dueck, A. C.,Ells, C., \u2026 Wenzel, L. (2021). SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ open,11(6), e045105. https:\/\/doi.org\/10.1136\/bmjopen-2020-045105.","DOI":"10.1136\/bmjopen-2020-045105."},{"issue":"1","key":"16341_CR63","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13063-016-1555-2","volume":"17","author":"CA Prinsen","year":"2016","unstructured":"Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, Williamson PR, Terwee CB. How to select outcome measurement instruments for outcomes included in a Core Outcome Set - a practical guideline. Trials. 2016;17(1):449. https:\/\/doi.org\/10.1186\/s13063-016-1555-2.","journal-title":"Trials"},{"issue":"2","key":"16341_CR64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/23971983211049846","volume":"7","author":"SL Murphy","year":"2022","unstructured":"Murphy SL, Berrocal VJ, Poole JL, Khanna D. Reliability, validity, and responsiveness to change of the Patient-Reported Outcomes Measurement Information System self-efficacy for managing chronic conditions measure in systemic sclerosis. J scleroderma Relat disorders. 2022;7(2):110\u20136. https:\/\/doi.org\/10.1177\/23971983211049846.","journal-title":"J scleroderma Relat disorders"},{"issue":"1","key":"16341_CR65","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12874-024-02188-4","volume":"24","author":"J Barbosa-Silva","year":"2024","unstructured":"Barbosa-Silva J, Calixtre LB, Von Piekartz D, Driusso P, Armijo-Olivo S. The minimal important difference of patient-reported outcome measures related to female urinary incontinence: a systematic review. BMC Med Res Methodol. 2024;24(1):60. https:\/\/doi.org\/10.1186\/s12874-024-02188-4.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"16341_CR66","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/bjd.18002","volume":"182","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Fuxench ZC, Simpson EL. Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Br J Dermatol. 2020;182(1):104\u201311. https:\/\/doi.org\/10.1111\/bjd.18002.","journal-title":"Br J Dermatol"},{"key":"16341_CR67","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2147\/JMDH.S419714","volume":"17","author":"P Cruchinho","year":"2024","unstructured":"Cruchinho P, L\u00f3pez-Franco MD, Capelas ML, Almeida S, Bennett PM, Miranda da Silva M, Teixeira G, Nunes E, Lucas P, Gaspar F. Translation, Cross-Cultural Adaptation, and Validation of Measurement Instruments: A Practical Guideline for Novice Researchers. J multidisciplinary Healthc. 2024;17:2701\u201328. https:\/\/doi.org\/10.2147\/JMDH.S419714. & Handovers4SafeCare","journal-title":"J multidisciplinary Healthc"},{"key":"16341_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1477-7525-3-23","volume":"3","author":"PW Stratford","year":"2005","unstructured":"Stratford PW, Riddle DL. Assessing sensitivity to change: choosing the appropriate change coefficient. Health Qual Life Outcomes. 2005;3:23. https:\/\/doi.org\/10.1186\/1477-7525-3-23.","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"16341_CR69","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s11136-025-03956-5","volume":"34","author":"CM Doran","year":"2025","unstructured":"Doran CM, Bryant J, Langham E, Bainbridge R, Shakeshaft A, Hobden B, Farnbach S, Freund M. Psychometric properties, and cultural appropriateness, of patient reported outcome measures for use in primary healthcare: a scoping review. Qual life research: Int J Qual life aspects Treat care rehabilitation. 2025;34(8):2137\u201349. https:\/\/doi.org\/10.1007\/s11136-025-03956-5.","journal-title":"Qual life research: Int J Qual life aspects Treat care rehabilitation"},{"issue":"11","key":"16341_CR70","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jamaoncol.2025.3153","volume":"11","author":"RS Huang","year":"2025","unstructured":"Huang RS, Chen D, Benour A, Cortez R, Mihalache A, Johnny C, Bezjak A, Olson RA, Raman S. Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer: A Systematic Review and Meta-Analysis. JAMA Oncol. 2025;11(11):1303\u201312. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3153.","journal-title":"JAMA Oncol"},{"issue":"3","key":"16341_CR71","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/09638288.2019.1626917","volume":"43","author":"DA Prud\u00eancio","year":"2021","unstructured":"Prud\u00eancio DA, Serafim TT, Mateus Lopes M, Maffulli APSR, N., Okubo R. Questionnaires and scales for assessment of ankle function: a systematic review of instruments translated and validated for Brazilian Portuguese. Disabil Rehabil. 2021;43(3):309\u201316. https:\/\/doi.org\/10.1080\/09638288.2019.1626917.","journal-title":"Disabil Rehabil"},{"issue":"9","key":"16341_CR72","doi-asserted-by":"publisher","first-page":"e073817","DOI":"10.1136\/bmjopen-2023-073817","volume":"13","author":"L Philipps","year":"2023","unstructured":"Philipps L, Foster S, Gardiner D, Gath J, Gillman A, Haviland J, Hill E, King D, Manning G, Stiles M, Hall E, Lewis R. Study within a trial of electronic versus paper-based Patient-Reported oUtcomes CollEction (SPRUCE): study protocol for a partially randomised patient preference study. BMJ open. 2023;13(9):e073817. https:\/\/doi.org\/10.1136\/bmjopen-2023-073817.","journal-title":"BMJ open"},{"key":"16341_CR73","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ymeth.2022.02.006","volume":"204","author":"A Vanier","year":"2022","unstructured":"Vanier A, Leroy M, Hardouin JB. Toward a rigorous assessment of the statistical performances of methods to estimate the Minimal Important Difference of Patient-Reported Outcomes: A protocol for a large-scale simulation study. Methods (San Diego Calif). 2022;204:396\u2013409. https:\/\/doi.org\/10.1016\/j.ymeth.2022.02.006.","journal-title":"Methods (San Diego Calif)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16341-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16341-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16341-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:09:01Z","timestamp":1787576941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16341-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16341"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16341-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a systematic review study for which no ethical approval is needed.","order":1,"name":"Ethics","label":"Ethics approval and consent to particpate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1014"}}